Valérie P.
- Country
- France
- Department
- Infectious Diseases
Research Overview
- OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Study
- Lenacapavir with Teropavimab and Zinlirvimab (twice‑yearly) versus Cabotegravir/Rilpivirine in virologically suppressed adults with HIV‑1
- Cohort study of human mpox virus disease
Data & Insights
Has run more than one trial at 67 of 220 partner sites.
Specializations
HIV Research Focus
This investigator specializes in studying novel therapeutic approaches for HIV-1 infection, with particular emphasis on antiretroviral regimens for treatment-naïve patients. Their research encompasses evaluation of various drug combinations including doravirine and dolutegravir-based therapies.
- Antiretroviral therapy optimization
- Two-drug versus three-drug regimens
- Viral suppression strategies
COVID-19 Clinical Research
The investigator conducts research in COVID-19 treatment strategies, focusing on both outpatient and hospitalized care. Their work includes studies of antiviral therapies in immunocompromised patients and evaluation of novel therapeutic approaches.
- Antiviral combination therapies
- Treatment of high-risk patients
- Immune modulation strategies
Emerging Infectious Diseases
The investigator's expertise extends to mpox virus disease and tuberculosis. Their research includes clinical outcomes studies and evaluation of preventive measures, including vaccine strategies and antimicrobial treatments.
- Mpox treatment and prevention
- Tuberculosis bactericidal therapy
- Progressive multifocal leukoencephalopathy
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.